Cardisio GmbH, a Frankfurt, Germany-based developer of a non-invasive screening method for heart diseases, raised €3.5m in funding.
Backers included Jim Davidson, the co-founder of Silver Lake, and Shawn O’Neill, who heads Silver Lake Waterman, in their personal capacities, as well as several other previous and new private investors based in the US and Germany.
The company intends to use the funds to expand its market reach and clinical trials in Germany and other European countries as well as to advance FDA clearance in preparation for U.S. market entry.
Cardisio is a mobile health tech company that uses artificial intelligence in a non-invasive screening test for coronary and structural heart diseases. The Cardisiography test can detect heart disease early, allowing for preventive treatment to avoid a potentially fatal heart attack. Cardisiography analyzes the individual three-dimensional electrophysical profile of the heart and recognizes pathological patterns of heart diseases using a proprietary algorithm and neural networks (AI). The test requires a PC to access the web service (Cardisio Cloud), a data collector (e.g. a Cardisiograph) and commercially available ECG cables as well as five disposable electrodes.
Cardisiographies are currently available for investigational use only in the United States. Final performance specifications and claims are subject to change pending the completion of regulatory market-access activities.
The company also has offices in Berlin and San Francisco.